One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2021-148778
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 14 |
Affiliation: Roche (Switzerland), Institut d'Investigació Biomédica de Bellvitge, University of Barcelona, Institut Català d'Oncologia, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Inserm, Centre Hospitalier Universitaire de Rennes, University of Rennes, Claude Bernard University Lyon 1, Hospices Civils de Lyon, University of Michigan–Ann Arbor, Centre Hospitalier Universitaire de Lille, Wroclaw Medical University, Rigshospitalet, Humanitas University, Roche (United Kingdom), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Ghent University Hospital, Universitair Ziekenhuis Brussel, Royal Melbourne Hospital, University of Melbourne, Peter MacCallum Cancer Centre, Universidad Complutense de Madrid, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, National Taiwan University HospitalGlofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
